Our medicines

We are a global biopharmaceutical company focused on helping to address the unmet medical needs of patients with serious diseases. In 2022, we invested $9.5 billion in R&D, which included the discovery and development of new medicines.

Report side effects or product quality complaints

Report side effects or product quality complaints about legacy celgene products (ABRAXANE®, IDHIFA®, INREBIC®, ISTODAX®, POMALYST®, REBLOZYL®, REVLIMID®, THALOMID®, VIDAZA®)

Below is a list of our company's marketed products. Any linked documents and websites are intended only for U.S. residents 18 years or older, as the availability of medicines and the indications for which they are approved can vary with country and region. 

Legacy brands

Prescribing information

Please click below to see the full U.S. Prescribing Information, including Boxed WARNING and Medication Guide/Patient Information for: